US20030108657A1 - Process for the preparation of one or more statins by frementation - Google Patents
Process for the preparation of one or more statins by frementation Download PDFInfo
- Publication number
- US20030108657A1 US20030108657A1 US10/072,570 US7257002A US2003108657A1 US 20030108657 A1 US20030108657 A1 US 20030108657A1 US 7257002 A US7257002 A US 7257002A US 2003108657 A1 US2003108657 A1 US 2003108657A1
- Authority
- US
- United States
- Prior art keywords
- amount
- food product
- statins
- fermentation
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract description 91
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000008569 process Effects 0.000 title claims abstract description 16
- 238000000855 fermentation Methods 0.000 claims abstract description 88
- 230000004151 fermentation Effects 0.000 claims abstract description 88
- 235000013305 food Nutrition 0.000 claims abstract description 72
- 239000004615 ingredient Substances 0.000 claims abstract description 23
- 239000000758 substrate Substances 0.000 claims abstract description 17
- 229940068065 phytosterols Drugs 0.000 claims abstract description 12
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 11
- 241000233866 Fungi Species 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 10
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 9
- 229930182490 saponin Natural products 0.000 claims abstract description 9
- 235000017709 saponins Nutrition 0.000 claims abstract description 9
- 150000007949 saponins Chemical class 0.000 claims abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 7
- 235000010469 Glycine max Nutrition 0.000 claims description 48
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims description 29
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 28
- 239000003921 oil Substances 0.000 claims description 26
- 244000068988 Glycine max Species 0.000 claims description 23
- 235000006539 genistein Nutrition 0.000 claims description 20
- 229940045109 genistein Drugs 0.000 claims description 20
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 20
- 235000013310 margarine Nutrition 0.000 claims description 18
- 239000003264 margarine Substances 0.000 claims description 13
- 235000013361 beverage Nutrition 0.000 claims description 10
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 claims description 8
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 claims description 8
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000008157 edible vegetable oil Substances 0.000 claims description 6
- 235000012054 meals Nutrition 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 235000015496 breakfast cereal Nutrition 0.000 claims description 2
- 235000015071 dressings Nutrition 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 239000000047 product Substances 0.000 description 57
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 27
- 239000002609 medium Substances 0.000 description 27
- 235000019198 oils Nutrition 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 240000007594 Oryza sativa Species 0.000 description 20
- 235000007164 Oryza sativa Nutrition 0.000 description 20
- 239000000203 mixture Substances 0.000 description 17
- 235000007189 Oryza longistaminata Nutrition 0.000 description 15
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 15
- 235000008696 isoflavones Nutrition 0.000 description 15
- 239000000284 extract Substances 0.000 description 14
- 239000003925 fat Substances 0.000 description 13
- 235000019197 fats Nutrition 0.000 description 13
- 150000002515 isoflavone derivatives Chemical class 0.000 description 13
- 235000007240 daidzein Nutrition 0.000 description 12
- 238000000605 extraction Methods 0.000 description 10
- -1 pravastatin Chemical class 0.000 description 10
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 235000013339 cereals Nutrition 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 239000002054 inoculum Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 6
- 235000019486 Sunflower oil Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 6
- 239000003549 soybean oil Substances 0.000 description 6
- 235000012424 soybean oil Nutrition 0.000 description 6
- 239000002600 sunflower oil Substances 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 241000031003 Monascus ruber Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000004040 coloring Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- 239000002028 Biomass Substances 0.000 description 4
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000008821 health effect Effects 0.000 description 4
- 229960004844 lovastatin Drugs 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 3
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 3
- 229930185723 monacolin Natural products 0.000 description 3
- 229930188430 monakolin Natural products 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000001965 potato dextrose agar Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002488 Hemicellulose Polymers 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Chemical compound C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000008466 glycitein Nutrition 0.000 description 2
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 2
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229940026314 red yeast rice Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 238000010563 solid-state fermentation Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- CDDWAYFUFNQLRZ-KJVHGCRFSA-N (3beta,21beta,22beta)-olean-12-ene-3,21,22,24-tetrol Chemical compound C([C@@]12C)C[C@H](O)[C@](C)(CO)[C@@H]1CC[C@]1(C)[C@@H]2CC=C2[C@@H]3CC(C)(C)[C@@H](O)[C@@H](O)[C@]3(C)CC[C@]21C CDDWAYFUFNQLRZ-KJVHGCRFSA-N 0.000 description 1
- YOQAQNKGFOLRGT-UXXABWCISA-N (3beta,22beta)-olean-12-ene-3,22,24-triol Chemical compound C1C[C@H](O)[C@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)[C@H](O)CC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C YOQAQNKGFOLRGT-UXXABWCISA-N 0.000 description 1
- TUZYXOIXSAXUGO-JFBQIPGGSA-N (3r,5r)-7-[(2s,6s,8s,8ar)-6-hydroxy-2-methyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C1=C[C@H](C)C(CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-JFBQIPGGSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- KXPKWHNZKVLCRR-UHFFFAOYSA-N 6-aminopyrimidine-4-carboxylic acid Chemical compound NC1=CC(C(O)=O)=NC=N1 KXPKWHNZKVLCRR-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- IBZLICPLPYSFNZ-UHFFFAOYSA-N Astragaloside VIII Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4)C)(C)CC3)(C)CC2)(C)CO)OCC(O)C1O IBZLICPLPYSFNZ-UHFFFAOYSA-N 0.000 description 1
- KFFJPIQLAPHYBF-UHFFFAOYSA-N Azukisaponin V Natural products COC(=O)C1OC(OC2CCC3(C)C(CCC4(C)C3CC=C5C6CC(C)(C)CC(O)C6(O)CCC45C)C2(C)CO)C(OC7OC(CO)C(O)C(O)C7OC8OC(C)C(O)C(O)C8O)C(O)C1O KFFJPIQLAPHYBF-UHFFFAOYSA-N 0.000 description 1
- BJXXHUMOEJBIJH-VKHMYHEASA-N CC(=O)[C@H](C)C(O)O Chemical compound CC(=O)[C@H](C)C(O)O BJXXHUMOEJBIJH-VKHMYHEASA-N 0.000 description 1
- KGAYOPFSUQMTPR-WUCPZUCCSA-N CC(O)[C@H](C)C(O)O Chemical compound CC(O)[C@H](C)C(O)O KGAYOPFSUQMTPR-WUCPZUCCSA-N 0.000 description 1
- WLAMNBDJUVNPJU-BYPYZUCNSA-N CC[C@H](C)C(=O)O Chemical compound CC[C@H](C)C(=O)O WLAMNBDJUVNPJU-BYPYZUCNSA-N 0.000 description 1
- BIWVHGWGBMHTTP-BYPYZUCNSA-N CC[C@H](C)C(O)O Chemical compound CC[C@H](C)C(O)O BIWVHGWGBMHTTP-BYPYZUCNSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 241001114512 Doratomyces Species 0.000 description 1
- DWONJCNDULPHLV-HOTGVXAUSA-N Enterodiol Chemical compound C([C@@H](CO)[C@H](CO)CC=1C=C(O)C=CC=1)C1=CC=CC(O)=C1 DWONJCNDULPHLV-HOTGVXAUSA-N 0.000 description 1
- AOJXPBNHAJMETF-UHFFFAOYSA-N Enterodiol Natural products OCC(Cc1ccc(O)cc1)C(CO)Cc2ccc(O)cc2 AOJXPBNHAJMETF-UHFFFAOYSA-N 0.000 description 1
- HVDGDHBAMCBBLR-UHFFFAOYSA-N Enterolactone Natural products OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000221929 Hypomyces Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- URRZRRQMNMZIAP-UHFFFAOYSA-N Kudzusapogenol C Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)C(O)CC3(C)CCC21C URRZRRQMNMZIAP-UHFFFAOYSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000222350 Pleurotus Species 0.000 description 1
- 239000004614 Process Aid Substances 0.000 description 1
- 241000233639 Pythium Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- VNGUCOGHCJHFID-UHFFFAOYSA-N Soyasapogenol C Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)C=CC3(C)CCC21C VNGUCOGHCJHFID-UHFFFAOYSA-N 0.000 description 1
- VNGUCOGHCJHFID-FLZFTVBESA-N Soyasapogenol C Chemical compound C([C@@]12C)C[C@H](O)[C@](C)(CO)[C@@H]1CC[C@]1(C)[C@@H]2CC=C2[C@@H]3CC(C)(C)C=C[C@]3(C)CC[C@]21C VNGUCOGHCJHFID-FLZFTVBESA-N 0.000 description 1
- JAQZKPHHLRTVCY-UHFFFAOYSA-N Soyasapogenol D Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CCC2=C3CC(C)(C)CC(OC)C3(C)CCC21C JAQZKPHHLRTVCY-UHFFFAOYSA-N 0.000 description 1
- JAQZKPHHLRTVCY-ZHRKTGFNSA-N Soyasapogenol D Chemical compound C([C@@]12C)C[C@H](O)[C@](C)(CO)[C@@H]1CC[C@]1(C)[C@@H]2CCC2=C3CC(C)(C)C[C@@H](OC)[C@]3(C)CC[C@]21C JAQZKPHHLRTVCY-ZHRKTGFNSA-N 0.000 description 1
- FTPPTNQVRLPEAE-UHFFFAOYSA-N Soyasapogenol-E Natural products CC1(C)CC(=O)C2(C)CCC3C(=CCC4C3(C)CCC5C(C)(CO)C(O)CCC45C)C2(C)C1 FTPPTNQVRLPEAE-UHFFFAOYSA-N 0.000 description 1
- JFHRJMPZZYINAI-UHFFFAOYSA-N Soyasaponin I Natural products CC1OC(OC2C(O)C(O)C(CO)OC2OC3C(O)C(O)C(CO)OC3OC4CCC5(C)C(CCC6(C)C5CC=C7C8CC(C)(C)CC(O)C8(C)CCC67C)C4(C)CO)C(O)C(O)C1O JFHRJMPZZYINAI-UHFFFAOYSA-N 0.000 description 1
- IBZLICPLPYSFNZ-IVWMTKFPSA-N Soyasaponin II Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H](O[C@@H]([C@@H](O)[C@@H]2O)C(O)=O)O[C@@H]2[C@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@@]6(C)[C@H](O)CC(C)(C)C[C@H]6C5=CC4)C)(C)CC3)(C)CC2)(C)CO)OC[C@H](O)[C@@H]1O IBZLICPLPYSFNZ-IVWMTKFPSA-N 0.000 description 1
- PZLAZXBSOCTDBG-UHFFFAOYSA-N Soyasaponin II Natural products CC1OC(OC2C(O)C(O)COC2OC3C(O)C(O)C(CO)OC3OC4CCC5(C)C(CCC6(C)C5CC=C7C8CC(C)(C)CC(O)C8(C)CCC67C)C4(C)CO)C(O)C(O)C1O PZLAZXBSOCTDBG-UHFFFAOYSA-N 0.000 description 1
- UZUYQJHHUUDLDJ-UHFFFAOYSA-N Soyasaponin III Natural products CC1(C)CC(O)C2(C)CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(C)(CO)C5CCC34C)C2C1 UZUYQJHHUUDLDJ-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 0 [1*]C1C=C2C=C[C@H](C)C(CC[C@]3([H])C[C@@H](O)CC(=O)O3)[C@@]2([H])C([2*])C1 Chemical compound [1*]C1C=C2C=C[C@H](C)C(CC[C@]3([H])C[C@@H](O)CC(=O)O3)[C@@]2([H])C([2*])C1 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical class CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012182 cereal bars Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229930016834 coumestan Natural products 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- WWSNTLOVYSRDEL-UHFFFAOYSA-N desmethylmonacolin J Natural products CC1C=CC2=CCCC(O)C2C1CCC1CC(O)CC(=O)O1 WWSNTLOVYSRDEL-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HVDGDHBAMCBBLR-WMLDXEAASA-N enterolactone Chemical compound OC1=CC=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-WMLDXEAASA-N 0.000 description 1
- 235000019126 equol Nutrition 0.000 description 1
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical class C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- BKZPCUPKVCPRQW-UHFFFAOYSA-N monakolin L Natural products CC1C=CC2=CC(C)CCC2C1CCC1CC(O)CC(=O)O1 BKZPCUPKVCPRQW-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- CDDWAYFUFNQLRZ-UHFFFAOYSA-N soyasapogenol A Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)C(O)C(O)C3(C)CCC21C CDDWAYFUFNQLRZ-UHFFFAOYSA-N 0.000 description 1
- MADZMXIFUWFDJK-AEARDBQCSA-N soyasapogenol B Natural products CC1(C)C[C@@H](O)[C@]2(C)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)C(=O)O)[C@](C)(CO)[C@@H]5CC[C@@]34C)[C@H]2C1 MADZMXIFUWFDJK-AEARDBQCSA-N 0.000 description 1
- FNRBOAGVUNHDIL-LMZUXBMISA-N soyasapogenol E Chemical compound C([C@@]12C)C[C@H](O)[C@](C)(CO)[C@@H]1CC[C@]1(C)[C@@H]2CC=C2[C@@H]3CC(C)(C)CC(=O)[C@]3(C)CC[C@]21C FNRBOAGVUNHDIL-LMZUXBMISA-N 0.000 description 1
- PTDAHAWQAGSZDD-IOVCITQVSA-N soyasaponin I Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H](O[C@@H]([C@@H](O)[C@@H]2O)C(O)=O)O[C@@H]2[C@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@@]6(C)[C@H](O)CC(C)(C)C[C@H]6C5=CC4)C)(C)CC3)(C)CC2)(C)CO)O[C@H](CO)[C@H](O)[C@@H]1O PTDAHAWQAGSZDD-IOVCITQVSA-N 0.000 description 1
- OKIHRVKXRCAJFQ-AHBDIROXSA-N soyasaponin III Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@]1(CO)C)C)(C)CC[C@@]1(C)[C@H](O)CC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O OKIHRVKXRCAJFQ-AHBDIROXSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000002328 sterol group Chemical group 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000011867 sweet spreads Nutrition 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000011514 vinification Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 229940072168 zocor Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/38—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/02—Whey; Whey preparations containing, or treated with, microorganisms or enzymes
- A23C21/026—Whey; Whey preparations containing, or treated with, microorganisms or enzymes containing, or treated only with, lactic acid producing bacteria, bifidobacteria or propionic acid bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1315—Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0056—Spread compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/40—Meat products; Meat meal; Preparation or treatment thereof containing additives
- A23L13/42—Additives other than enzymes or microorganisms in meat products or meat meals
- A23L13/424—Addition of non-meat animal protein material, e.g. blood, egg, dairy products, fish; Proteins from microorganisms, yeasts or fungi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/40—Meat products; Meat meal; Preparation or treatment thereof containing additives
- A23L13/45—Addition of, or treatment with, microorganisms
- A23L13/46—Addition of, or fermentation with fungi, e.g. yeasts; Enrichment with dried biomass other than starter cultures
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
- A23L13/65—Sausages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
- A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to process for the preparation of one or more statins by fermentation.
- the invention further relates to food product comprising one or more statins.
- Statins are compounds that are known to have a lowering effect on levels of low-density lipoprotein cholesterol (LDL-choloesterol) in the human blood. Elevated LDL-cholesterol levels (hypercholesterolemia) is directly related to increased risk of coronary heart disease. Statins inhibit the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, the rate-determining step in the cholesterol biosynthesis.
- HMG-CoA hydroxymethylglutaryl coenzyme A
- statins are also reported in fermentation using fungi other than the above-mentioned Monascus species. It has been shown that statins can be produced by a variety of filamentous fungi, including Monascus, Aspergillus, Penicillium, Pleurotus, Pythium, Hypomyces, Paelicilomyces, Eupenicillium, and Doratomyces.
- statins used in pharmaceutical preparations involves many process-steps, in which ingredients are used that are not commonly used in the food industry.
- the many process steps increase costs compared to processes having less process steps. For these reasons the statins prepared for pharmaceutical use are not used in the foods industry.
- red rice As a food product, rice fermented with a red Monascus fungus (red rice) has been known and used for hundreds of years in China. Red rice was used and still is used in wine making, as a food-colouring agent and as drug in traditional Chinese medicine. We have found that most red rice available on the market contains no statins or statins in very low amounts. The Food and Drug Administration has concluded that red yeast rice available in the market does not contain significant amounts of lovastatin (FDA, Docket No. 97-0441, Final Decision).
- WO 99/23996 describes a composition for treating elevated serum cholesterol and/or triglycerides comprising a red rice product containing at least 0.05% lovastatin by weight.
- Red rice powder capsules are sold as dietary supplements under the name of Cholestin by the firm Pharmanex. Pharmanex also sells a Cholestin bar containing red yeast rice (Monascus purperus went).
- Red rice has an intensive red colour.
- the intensive red colour of red rice is an advantage when it is used as colouring agent, it is a disadvantage when it is used in food products.
- Due to the intense red colour of red-rice products the foods prepared from red rice are coloured, depending on the amount of red-rice product added to the food product yellow, orange or red. The higher the amount of red rice added to the food, the more intense is the red colour of the food product.
- a relatively large amount of red rice has to be added in order to add enough statins. This results in a red colour of the products that cannot be avoided.
- red rice colouring is undesirable.
- consumers are reluctant to use products of which the colour has changed from that they are used to.
- spreads including margarine, butter, low fat spreads or salad oils are considered unacceptable by customers, when the colour of such a product is orange or red.
- these type of products have been found by us to be excellent vehicles of the daily intake of amounts of statins sufficient to obtain a blood LDL-cholesterol lowering effect.
- a further object of the invention is to increase the health effects of the known food products comprising statin.
- Another object is to provide a process for the preparation of a food product comprising statin, which involves less process steps than in the preparation of statins as a pharmaceutical drug.
- Another object is to provide such a process, which avoids the use of ingredients or process aids that are not commonly used in the food industry.
- One or more of these objects are attained by a process for the preparation of one or more statins by fermentation, wherein a substrate is fermented with statins producing fungus, characterized in that substrate comprises more than 20% by weight of soy ingredients.
- a food product comprising:
- the amount of a) is 5-100 mg/kg and the amount of b) 1 wt. or higher. More preferably the amount of b) is 5 wt. % or higher.
- the substrate for the Monascus fermentation is soybeans and/or soybean ingredients
- the red colouring of the fermented product as in red rice fermentation is avoided, i.e. a non-coloured or only slightly coloured fermentation product is obtained.
- compounds having a positive health effect, which are present in soybeans are also present in the fermented product. These compounds include, but are not limited to polyunsaturated fatty acids, phytosterols, proteins, peptides, dietary fibers including soluble fibers, polyphenols and saponins.
- the food product according to the invention has increased health effects compared to the known food products comprising statin.
- Statins are defined as substances having the structural formula, presented in formula (1).
- R1 and R2 can be any group.
- Preferred statins are those given in table 1. TABLE 1 Preferred statins according to formula (1) R1 R2 monakolin K CH3 monakolin L CH3 H monakolin J CH3 OH monakolin X CH3 monakolin M CH3 compactin (ML-236B) H ML-236-A H OH NL-236-C H H
- Polyphenols herein are polyphenols having plant origin. These include flavenoids, which include isoflavones.
- the polyphenols include isoflavones, stilbenes, lignans, coumestans and resorcyclic acid lactones.
- isoflavones are genistein, daidzein, equol, glycitein, biochanin A, coumestrol, maitaresinol, formononetin, O-desmethylengolesin, enterolactone and enterodiol.
- Preferred isoflavones according to the invention are genistein and daidzein and glycitein, which are present in soybeans.
- Saponins are herein derived as ⁇ -D-glucopyranosiduronic acid derivates.
- Examples of saponins are Soya sapogenol A,B,C,D and E, Soyasaponin I, II and III, as described in Anlagen Lexikon, B.Behr's Verlag GmbH & Co. Hamburg, Bd.2, L-Z -3, 1993, pages 550-552.
- Polyunsaturated fatty acid esters are defined as fatty acid esters having more than one unsaturated group in the fatty acid chain.
- Examples of polyunsaturated fatty acid esters are linoleic acid esters, linolenic acid esters, arachidonic acid esters.
- Dietary fibers are herein a collective term for a variety of plant substances, that are resistant to digestion by the human gastrointestinal enzymes. Depending on their solubility, dietary fibers can be classified into insoluble (cellulose, some hemicelluloses, lignins), and soluble (remainder of the hemicelluloses, gums, mucilages. Soybean cotyledon fibers comprise both soluble and insoluble dietary fibers.
- phytosterols are herein defined as sterol compounds produced by plants, which are structually very similar to cholesterol except that they contain some substitutions at the C24 position on the sterol side chain.
- the phytosterols include 4-desmethylsterol, 4-monomethylsterols, 4,4′-dimethylsterols and mixtures thereof. Examples of such phytosterols are ⁇ -sitosterol, campesterol, stigmasterol.
- the term phytosterols herein also includes phytostanols, the saturated equivalents of phytosterols.
- soy actives Polyphenols, polyunsaturated fatty acids, phytosterols, proteins, peptides, dietary fibers, and saponins will hereinafter collectively be referred to as soy actives.
- statins given herein are the sum of the amounts of individual statins, as e.g. determined by chromatography, unless otherwise indicated.
- the substrate is herein defined as total of compounds in the fermentation medium, without the solvent, for instance without water, in case a liquid, water based fermentation medium is used. In case no solvent is present the substrate equals the fermentation medium.
- soy actives are expressed as the sum (wt. % or ppm) of polyunsaturated fatty acids, phytosterols, proteins, peptides, dietary fibers including soluble fibers, polyphenols and saponins.
- the food product has a Hue a* value of less than 20, preferably less than 20, most preferably less than 0.
- the Hue a* value is determined as described hereinafter in the examples.
- a food product according to the invention does not include products especially suitable for the feeding of animals (feed).
- Several food products may be prepared according to the invention, for example, spreads, soups, noodles, ice-cream, sauces, dressing, snacks, cereals, beverages, bread, biscuits, other bakery products, sweets, bars, chocolate, chewing gum, dairy products, dietetic products e.g. slimming products or meal replacers etc.
- statins and soy actives are present in the food product in an amount sufficient to obtain a blood LDL-cholesterol lowering effect if the food product is used according to the common needs of the consumer.
- the amount of statin is 5-500 mg/kg and the amount of soy actives is 1 wt. or higher. More preferably the amount of soy actives is 5 wt. % or higher or 10 wt % or higher. Most preferably the amount of soy actives is 20 wt. % or higher.
- table 2 indicates a number of products, which may be prepared according to the invention, and a typical serving size.
- Product Daily Serving Margarine 15 g Meat product 50 g Dressing 30 g Sweet 10 g Bar 75 g Meal replacer drink 330 ml Beverages 200 ml
- the food product according to the invention comprises statin and non-glycosylated isoflavone.
- isoflavones are present substantially in the glycosylated form. Typically about 5 wt. % of the isoflavones is present in the non-glycosylated form.
- the most important glycosylated isoflavones are genistin, daidzin and glycetin.
- the non-glycosylated forms are respectively genistein, daidzein and glycetein. Genistein, daidzein and glycetein have been reported to have advantageous health effects, including estrogenic and antioxidant properties.
- the invention therefore further relates to a food product wherein the amount of statin is 5-500 mg/kg, and an amount of genistein and genistin, wherein the amount of genistein is 10-99 wt. %, preferably 15-99 wt. %, more preferably 20-95 wt. %, still more preferably 20-90 wt. %, most preferably 20-80 wt. % of the sum of the amounts of genistein and genistin.
- the invention therefore further relates to a food product wherein the amount of statin is 5-500 mg/kg, and an amount of daidzein, wherein the amount of daidzein is 10-99 wt. %, preferably 15-99 wt. %, more preferably 20-95 wt. %, still more preferably 20-90 wt. %, most preferably 20-80 wt. % of the sum of the amounts of daidzein and daidzin.
- the absolute amounts of genistein and daidzein may, for each food product, be adjusted by the skilled person to a desired level. This may for instance be done by selection of the soy material to be fermented from materials having a different isoflavone content, by adjustment of the fermentation conditions, such as fermentation time, and by selecting the amount of fermented soy added to the food product. In such way the amount may be adjusted to a desired daily intake of the isoflavones, that could be for instance 50-80 mg/day for genistein.
- the preferred absolute level of genistein in the food products according to the invention depends on the food type, and may be 50 mg/kg or more, more preferably 100 mg/kg or more, 200 mg/kg or more, 500 mg/kg or more and most preferably 200-5000 mg/kg. Also the absolute level of daidzein depends on the food type, and may be 50 mg/kg or more, more preferably 100 mg/kg or more, 200 mg/kg or more, 500 mg/kg or more and most preferably 200-5000 mg/kg.
- the food product according to the invention is a spread, meat product, sauce, such as soy sauce, vinegar, soup, bakery good, beverage or bar.
- sauce such as soy sauce, vinegar, soup, bakery good, beverage or bar.
- More preferred food products according to the invention are a spread, cereal bar, beverage or breakfast cereal.
- spreads according to the invention are oil in water or water in oil emulsions, although also spreads, which are substantially fat free, are covered.
- Spreads are to include margarines and liquid cooking products.
- the spreads may be spreadable and not pourable or may be pourable at the temperature of use e.g. 2-10° C.
- Fat levels may vary in a wide range e.g. full fat margarines with 60-90 wt. % of fat, medium fat margarines with 30-60 wt. % of fat, low fat products with 10-30 wt. % of fat and very low or fat free margarines with 0 to 10 wt. % of fat.
- the fat in the margarine or other spread may be any edible fat, often used are soybean oil, rapeseed oil, sunflower oil and palm oil. Fats may be used as such or in modified form e.g. hydrogenated, esterified, refined etc. Other suitable oils are well known in the art and may be selected as desired.
- the pH of a margarine or spread may advantageously be from 5.0 to 6.5, though other pH's are possible.
- Examples of spreads other than margarines are cheese spreads, sweet spreads, yoghurt spreads etc.
- Optional further ingredients of spreads may be emulsifiers, colourants, vitamins, preservatives, emulsifiers, gums, thickeners etc.
- the balance of the product will normally be water.
- a typical size for an average serving of margarine or other spreads is 15 grams.
- Preferred levels of statins in the margarine or spread are: 20-500 mg/kg statin, more preferred ranges are 50 to 250 mg/kg statin.
- Preferred food products according to the invention are beverages, for example tea, fruit juice, soft drinks, meal-replacers, etc. Meal replacer drinks will be described in more detail herein below. It will be apparent that similar levels and compositions apply to other beverages comprising statins and soy actives.
- a typical serving size of a beverage is taken to be 200 ml.
- Preferred levels of statins in a beverage are: 5-100 mg/kg, more preferably 10-80 mg/kg.
- these products often comprise a matrix of edible material wherein the statin and soy actives can be incorporated.
- the matrix may be fat based (e.g. couverture or chocolate) or may be based on bakery products (bread, dough, cookies etc).
- the food product is a cereal bar, in which the matrix is based on agglomerated cereal particles (rice, grain, nuts, raisins, fruit particles).
- the matrix material of a bar may be present in an amount of 60-95 wt. % of the weight of the bar, preferably 70-90 wt. % most preferred 75-85 wt %.
- ingredients in the cereal bar may be starch, sugar (e.g. 0-10 wt %), sirups, honey, milk solids, salt (e.g. 0-5 wt. %) calcium carbonate, vitamins, flavouring and colouring.
- the ingredients are usually mixed and cooked (e.g. by cooking-extruding) to produce the (cereal) bar.
- a typical size for a bar could be from 20 to 200 g, generally from 40 to 100 g.
- Preferred level in such products would be: 25 to 500 mg/kg statin. More preferred range for this level is 50 to 300 mg/kg.
- flavouring materials may be added to the product such as flavouring materials, vitamins, minerals etc.
- a substrate prepared from soybeans and/or ingredients thereof is fermented with a statin producing fungus and the fermentation product is used in the preparation of a food product.
- a statin producing fungus is Monascus.
- Fermentation is conducted in known way.
- the fermentation is conducted in at least one fermentation vessel (fermenter) in which a medium comprising soybeans and/or ingredients thereof is present.
- the fermentation is started (inoculated) by adding a suspension of spores of the Monascus fungus (inoculum), which has been prepared by fermenting Monascus fungus on a separate medium.
- the fermentation may be executed batchwise or as a continuous process.
- the fermentation product is used in the preparation of the food products according to the invention.
- the medium used in the fermenter may be solid or liquid.
- the medium is solid, most preferred the medium substantially consists of crushed whole soybeans, which have been soaked with water (e.g. 30 wt % water).
- water e.g. 30 wt % water
- the medium is liquid, usually water is present as major constituent of the medium.
- Whole soybean are preferably used as a substrate for the fermentation.
- Typical composition of whole soybeans is 42% wt % protein, 20 wt % oil, 35% wt % total carbohydrates, 5 wt % ash and 5.5 wt % crude fiber (Kawamura, S., Tech. Bull. Faculty Agric., Kagawa Univ., 18, 117 (1967)).
- parts or ingredients of soybean may be used in the medium for the fermenter, for instance soy protein (including textured vegetable protein), soy milk, soy-flakes etc. Care has to be taken that the medium contains compounds that can provide a carbon source and a nitrogen source for growth of the Monascus fungus.
- the Monascus fungus used according to the invention may be any Monascus fungus that produces statins.
- the fungus is chosen from the group of Monascus ruber Most preferred is Monascus ruber F125 M1-4.
- Strains F125 and F125 M1-4 are deposited at the Centraal Bureau voor Schimmelculturen (CBS) as no. CBS 109070 on 14.11.2000 and no. CBS 109269 on 23.01.2001.
- the medium will ordinarily be sterilized before fermentation, e.g. by heat treatment, like pasteurization.
- the medium in the fermenter may contain other substances, which may aid the fermentation, for instance sugars, amino acids and vitamins.
- the fermentation may be carried out in a manner, which can be determined by the skilled person on the basis of common general knowledge of fermentation technology. As illustration preferred embodiments are described hereunder.
- the fermentation temperature may be important.
- the temperature is preferably in the range of 10 to 37, ° C. more preferably 20 to 30° C. We have found that at 37° C. and higher the production of statins decreases.
- the medium is aerated, e.g. by stirring, shaking etc.
- Aeration may be carried out by blowing air through the fermentation medium.
- the air is wholly or partly saturated with water vapour in case solid state fermentation is used. This avoids drying out of the fermentation medium.
- the relative levels of statins to soy actives will depend on the fermentation time.
- the fermentation time is therefore dependent on the desired amount of statins in the fermentation product.
- Preferred fermentation time is 1-60 days, more preferably 1-50 days, still more preferably 15-40 most preferably 20-30 days.
- the fermentation product Prior to addition to the food product, the fermentation product may be subjected to a separation step, to separate statins and soy actives from Monascus biomass in the fermentation product. This separation may be done with known separation techniques, e.g. filtration or centrifugation.
- the fermentation product may also be extracted and extract may be used in the preparation of the food product.
- Preferred extraction agents are food-grade extraction agents. More preferred extraction agent is ethanol. Most preferred extraction agent is vegetable oil, e.g. soybean oil or sunflower oil.
- the extraction may be done on the fermentation product.
- the Monascus biomass may be separated from the fermentation product prior to extraction, e.g. by filtration.
- the Monascus biomass may be separately extracted and the resulting extract can also be used in the preparation of the food product.
- Extracts may be used as such in the preparation of food products.
- extraction solvent may be removed from the extracts, e.g. by evaporation of the extraction solvent.
- edible oil may be used as extractant, the edible oil is preferably vegetable oil, such as for instance soy bean oil or sunflower oil.
- vegetable oil such as for instance soy bean oil or sunflower oil.
- the extractant e.g. vegetable oil is added to the fermentation medium during fermentation.
- the amount of statin produced is preferably at least 5 wt. % oil (w/w on substrate), more preferably more than 10 wt. %, most preferably at least 20 wt. %, being present in the substrate during fermentation.
- the oil is edible oil, more preferably vegetable edible oil, such as for instance sunflower oil or soybean oil. Though animal and vegetable fat may be used these are less preferred for hearth health reasons.
- the fermentation product may directly be added to food product ingredients in the process of preparation of the food products according to the invention. It can be added to the other ingredients of the food product composition, or it may be added to part of the ingredients, before other ingredients are added. If more than one phase is present in the food product the fermentation product may be present in one or more of these phases. Preferably the fermentation product will substantially be present in an oil phase, if such oil phase is present.
- Monascus ruber strain F125 was cultivated in malt water liquid medium at 30° C. for 4 days. Of this culture, 1 ml was used as an inoculum for a Hybond-N filter (Amersham, UK) placed on a YE plate (4% glucose, 0.3% KH 2 PO 4 , 1.0% yeast extract (Difco), 1.5% agar). After 3 days incubation at 30° C., the spores were harvested by washing the filters with 10 ml physiological saline containing 0.1% Tween 80. The spores were filtered 4 times through Mira cloth filters to obtain a hyphae free spore suspension. This suspension was used for subsequent mutagenesis.
- the spores were diluted to a concentration of 10 8 spore/ml then exposed to UV light at an intensity of 100 joules/m 2 .
- the mutagenised spores were plated on Potato Dextrose Agar (Oxoid) and incubated for 3 weeks.
- One of the resulting colonies, which had a lighter colour than the others was selected and is herein defined as Monascus strain F125 M1-4.
- Monascus f125M1-4 spores were prepared by harvesting Monascus mycelium from a PDA (potato dextrose agar) (oxoid) slope by washing with 5 ml physiological saline and incubating the mycelium in 150 ml malt water (oxoid) for 4 days at 30° C. The spores were harvested by filtration through a Mira cloth filter.
- a shake flask containing soybeans is inoculated with filamentous spores suspended in a physiological water solution containing 0.1 wt % Tween 80 (polyoxyethylene sorbitan fatty acid ester, available from ICI Specialty ChemicalsTM). This shake flask is incubated to let the mould grow. This resulted in a Monascus spore suspension, which was adjusted by dilution to a concentration of 1*10 6 spores/ml.
- Tween 80 polyoxyethylene sorbitan fatty acid ester
- the shake flasks were each inoculated with 1 ml of the prepared Monascus spore suspension and incubated for 30 days at 30° C. A sample from the shake flask was taken every week to monitor the statin production.
- the fermentation product samples are extracted in a 50 ml tube (Falcon) by adding 6 ml of a mixture of acetonitril, water and phosphoric acid (1:1:0.05, v/v/v). The mixture is blended with an Ultraturrax for 1 min. The mixture was then incubated at room temperature on a rollerbank for over 24 hours. Hereafter the samples were centrifuged and the supernatant liquid used for HPLC analysis. Samples were separated using HPLC analysis on a Shimadzu apparatus according to the method of Morovjan et al., J. chromatogr. A 763 (1997) 165-172.
- the system consists of the Shimadzu SCL-10A system controller, CTO-10AS column oven, LC-10AT vp pump system, RID-10A refraction index detector, SPD-M10A diode array detector and SIL-10AD autoinjector.
- a Waters NovaPak C18 (150 ⁇ 3.9 mm I.D., 4 ⁇ m) column was used operating at 25° C.
- the eluent was acetonitril-0.1% phosphoric acid (50:50,v/v) solution flowing at 1.5 ml/min. Runs were performed for 15 min.
- the detection was performed using a diode array detector from 190 nm up to 800 nm.
- the sum of the area of all peaks in the spectrum belonging to statins is measured. Comparison to a standard (Mevinolin, Sigma) allows the calculation of a statin content (expressed in mg/kg analysed product).
- the fermentation product was extracted with ethanol and acetonitril.
- the soybean extracts contained 0.0545 g statin/kg (ethanol extract) or 0.0978 g statin/kg (acetonitril extract) as determined by HPLC, as described under D.
- composition of the pourable margarine is given in table 3.
- TABLE 3 Composition of the pourable margarine of example 1.
- Amount Ingredient (wt. % on total) Sunflower oil 79.6 Rapeseed oil 1.95 hardened to a melting temperature of 70° C.
- Example 1 steps B to G were repeated, but instead of Monascus strain F125 M1-4, a Monascus strain isolated from red rice (commercial product from China) was used.
- step C.2. instead of 1 kg of soybeans, 1 kg of rice (Parboiled rice, Oryza) was used. After fermentation about 500 g rice remained.
- a spread having the composition as in table 4 was prepared. TABLE 4 Composition of spread of example 2 Ingredient Amount (wt % on total) Sunflower oil 69.295 Fat blend 10.5 Beta carotene 0.125 Monoglygceride (Hymono 0.08 8903) Water 13.33 Ethanol extract of 6.67 example 1C Total 100
- the fat blend was a mixture of 65 wt. % mid fraction of palm oil stearin and 35 wt % palm kernel oil.
- the spread was prepared by premixing the ingredients in a premix tank at 55° C. in a premix tank and feeding the premix to a Votator with two scraped surface heat exchangers (A-units) operated at 800 rotations per minute (rpm) and one crystallizer (C-unit) operated at 200 rpm.
- the configuration was A-A-C.
- the amount of statin in the spread was 74 mg/kg.
- the colour of the spread was not different from a control with no statins extract, but 20 wt. % water.
- 10 litre reactors were filled with 8 litres substrate (Glucose 20 9/1, glycerol 100 g/l, starch 20 g/l, NaNO3 2 g/l MgSO4 5 g/l) and set to an airflow of 6 volume change per minute (vvm).
- a pre-culture was prepared in YPD at 30° C. for two days and used to inoculate the fermentor with a concentration of 1 ⁇ 10 7 spores/l Monascus ruber F125M1-4. The cultures were incubated at 25° C. and 200 rpm for 3 weeks. After 22 days, 400 ml soybean oil was added to the 10 litre reactor.
- statins were found in the oil phase. A big difference is seen between the statin levels in the oil and the water phase.
- the supplementation of oil increases the total amount of statin in the reactor.
- a control reactor without oil supplementation contained 1.8 mg/l statins, while the reactor with oil supplementation shows a total amount of 83.4 mg/l statins.
- the reactor with oil supplementation shows a 45 times higher statin content compared with the amount of statins in the fermentation without oil.
- Steps A, B and D. were done according to example 1.
- a shake flask containing dehulled soybeans is inoculated with filamentous spores suspended in a physiological water solution containing 0.1 wt % Tween 80 (polyoxyethylene sorbitan fatty acid ester, available from ICI Specialty ChemicalsTM). This shake flask is incubated to let the mould grow. This results in a Monascus spore suspension, which was adjusted by dilution to a concentration of 1*10 6 spores/ml.
- Tween 80 polyoxyethylene sorbitan fatty acid ester
- the shake flasks were each inoculated with 1 ml of the prepared Monascus spore suspension and incubated for 30 days at 30° C. A sample from the shake flask was taken every week to monitor the statin production.
- step D results in a statin content of 2800 mg/kg product.
- the isoflavone concentration was measured according to the HPLC method described in Franke A.A., et al. (1998): HPLC analysis of isoflavonoids and other phenolic agents from foods and human fluids; Proceed. Soc. Exp. Biol. Med; 217 (3), 274-280.
- Table 3 shows that the amount of isoflavones in total in the fermentation product is slightly decreased compared to the non-fermented material, but surprisingly the amounts of genistein and daidzein are increased.
- the fermentation product contains substantial amounts of isoflavones in addition to the statin.
Abstract
A process is described for the preparation of one or more statins by fermentation, wherein a substrate is fermented with statins producing fungus wherein the substrate comprises more than 20% by weight of soy ingredients. Further a food product is described comprising an amount of one or more statins and an amount of one or more compounds chosen from the group: polyunsaturated fatty acids, phytosterols, proteins, peptides, dietary fibers, polyphenols and saponins, wherein the food product has a Hue a* value less than 20.
Description
- The present invention relates to process for the preparation of one or more statins by fermentation. The invention further relates to food product comprising one or more statins.
- Statins are compounds that are known to have a lowering effect on levels of low-density lipoprotein cholesterol (LDL-choloesterol) in the human blood. Elevated LDL-cholesterol levels (hypercholesterolemia) is directly related to increased risk of coronary heart disease. Statins inhibit the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, the rate-determining step in the cholesterol biosynthesis.
- Scientific research has confirmed the healthy properties of statins especially with respect to LDL blood-cholesterol and triglyceride levels lowering activities, both in animals and in humans (Li et al., Nutrition Research 18, 71-81 (1998); Heber et al., Am. J. Clin. Nutr. 69, 231-236 (1999)).
- Early reports of the effect of statins were made in 1979. The Japanese scientist Endo isolated a metabolite from Monascus that reduced artificially induced hyperlipoproteinemia in rats (Endo, J. Antibiotics 32, 852-854, (1979)). These metabolites are known as monacolins. Monacolin is identical to the cholesterol lowering pharmaceutical lovastatin. Lovastatin is sold by Merck co. under the tradename Mevacor. A derivative of lovastatin, simvastatin, is sold as a cholesterol-lowering drug under the name of Zocor. Other derivatives of lovastatin e.g. pravastatin, and mevastatin, are also sold as lipid lowering drugs against hypercholesterolemia. Monascus-extracts are sold in capsules in Japan as the dietary product Monacolin. The usual dose of the above statins is 20 mg/day, which results in at least 20% blood LDL-cholesterol lowering.
- The production of statins is also reported in fermentation using fungi other than the above-mentioned Monascus species. It has been shown that statins can be produced by a variety of filamentous fungi, including Monascus, Aspergillus, Penicillium, Pleurotus, Pythium, Hypomyces, Paelicilomyces, Eupenicillium, and Doratomyces.
- The preparation and purification of the statins used in pharmaceutical preparations involves many process-steps, in which ingredients are used that are not commonly used in the food industry. The many process steps increase costs compared to processes having less process steps. For these reasons the statins prepared for pharmaceutical use are not used in the foods industry.
- As a food product, rice fermented with a red Monascus fungus (red rice) has been known and used for hundreds of years in China. Red rice was used and still is used in wine making, as a food-colouring agent and as drug in traditional Chinese medicine. We have found that most red rice available on the market contains no statins or statins in very low amounts. The Food and Drug Administration has concluded that red yeast rice available in the market does not contain significant amounts of lovastatin (FDA, Docket No. 97-0441, Final Decision).
- WO 99/23996 describes a composition for treating elevated serum cholesterol and/or triglycerides comprising a red rice product containing at least 0.05% lovastatin by weight.
- Red rice powder capsules are sold as dietary supplements under the name of Cholestin by the firm Pharmanex. Pharmanex also sells a Cholestin bar containing red yeast rice (Monascus purperus went).
- Red rice has an intensive red colour. Whereas the intensive red colour of red rice is an advantage when it is used as colouring agent, it is a disadvantage when it is used in food products. Due to the intense red colour of red-rice products, the foods prepared from red rice are coloured, depending on the amount of red-rice product added to the food product yellow, orange or red. The higher the amount of red rice added to the food, the more intense is the red colour of the food product. In the known food products a relatively large amount of red rice has to be added in order to add enough statins. This results in a red colour of the products that cannot be avoided.
- In some food products the red rice colouring is undesirable. In particular in the western world, consumers are reluctant to use products of which the colour has changed from that they are used to. For example spreads, including margarine, butter, low fat spreads or salad oils are considered unacceptable by customers, when the colour of such a product is orange or red. However, at the same time these type of products have been found by us to be excellent vehicles of the daily intake of amounts of statins sufficient to obtain a blood LDL-cholesterol lowering effect.
- It is an object of the invention to provide a food product that has no undesired colouring due to the addition of statins. A further object of the invention is to increase the health effects of the known food products comprising statin. Another object is to provide a process for the preparation of a food product comprising statin, which involves less process steps than in the preparation of statins as a pharmaceutical drug. Another object is to provide such a process, which avoids the use of ingredients or process aids that are not commonly used in the food industry.
- One or more of these objects are attained by a process for the preparation of one or more statins by fermentation, wherein a substrate is fermented with statins producing fungus, characterized in that substrate comprises more than 20% by weight of soy ingredients.
- Further one or more of the above objects are attained by a food product comprising:
- a) an amount of one or more statins
- b) an amount of one or more compounds chosen from the group:
- polyunsaturated fatty acids, phytosterols, proteins, peptides, dietary fibers, including soluble fibers, polyphenols and saponins, wherein the food product has a Hue a value of less than 20, preferably less than 20, most preferably less than 0.
- Preferably the amount of a) is 5-100 mg/kg and the amount of b) 1 wt. or higher. More preferably the amount of b) is 5 wt. % or higher.
- We have found that when the substrate for the Monascus fermentation is soybeans and/or soybean ingredients, the red colouring of the fermented product as in red rice fermentation is avoided, i.e. a non-coloured or only slightly coloured fermentation product is obtained. Further we have found that compounds having a positive health effect, which are present in soybeans are also present in the fermented product. These compounds include, but are not limited to polyunsaturated fatty acids, phytosterols, proteins, peptides, dietary fibers including soluble fibers, polyphenols and saponins. As a result of the presence of these compounds in the fermentation product, the food product according to the invention has increased health effects compared to the known food products comprising statin.
- The following definitions will be used.
-
-
- Polyphenols herein are polyphenols having plant origin. These include flavenoids, which include isoflavones. The polyphenols include isoflavones, stilbenes, lignans, coumestans and resorcyclic acid lactones. Examples of isoflavones are genistein, daidzein, equol, glycitein, biochanin A, coumestrol, maitaresinol, formononetin, O-desmethylengolesin, enterolactone and enterodiol. Preferred isoflavones according to the invention are genistein and daidzein and glycitein, which are present in soybeans.
- Saponins are herein derived as β-D-glucopyranosiduronic acid derivates. Examples of saponins are Soya sapogenol A,B,C,D and E, Soyasaponin I, II and III, as described in Lebensmittel Lexikon, B.Behr's Verlag GmbH & Co. Hamburg, Bd.2, L-Z -3, 1993, pages 550-552.
- Polyunsaturated fatty acid esters are defined as fatty acid esters having more than one unsaturated group in the fatty acid chain. Examples of polyunsaturated fatty acid esters are linoleic acid esters, linolenic acid esters, arachidonic acid esters.
- Dietary fibers are herein a collective term for a variety of plant substances, that are resistant to digestion by the human gastrointestinal enzymes. Depending on their solubility, dietary fibers can be classified into insoluble (cellulose, some hemicelluloses, lignins), and soluble (remainder of the hemicelluloses, gums, mucilages. Soybean cotyledon fibers comprise both soluble and insoluble dietary fibers.
- Phytosterols are herein defined as sterol compounds produced by plants, which are structually very similar to cholesterol except that they contain some substitutions at the C24 position on the sterol side chain. The phytosterols include 4-desmethylsterol, 4-monomethylsterols, 4,4′-dimethylsterols and mixtures thereof. Examples of such phytosterols are β-sitosterol, campesterol, stigmasterol. The term phytosterols herein also includes phytostanols, the saturated equivalents of phytosterols.
- Polyphenols, polyunsaturated fatty acids, phytosterols, proteins, peptides, dietary fibers, and saponins will hereinafter collectively be referred to as soy actives.
- Unless otherwise indicated, the amounts given will be expressed, in wt. % or weight parts per million (ppm), mg/kg or g/kg, relative to the total weight of the food product, unless otherwise indicated.
- The amounts of statins given herein are the sum of the amounts of individual statins, as e.g. determined by chromatography, unless otherwise indicated.
- The substrate is herein defined as total of compounds in the fermentation medium, without the solvent, for instance without water, in case a liquid, water based fermentation medium is used. In case no solvent is present the substrate equals the fermentation medium.
- The protein amounts given herein are the sum of the amounts of individual proteins, unless otherwise indicated.
- The amounts of soy actives are expressed as the sum (wt. % or ppm) of polyunsaturated fatty acids, phytosterols, proteins, peptides, dietary fibers including soluble fibers, polyphenols and saponins.
- The food product has a Hue a* value of less than 20, preferably less than 20, most preferably less than 0. The Hue a* value is determined as described hereinafter in the examples.
- Preferably a food product according to the invention does not include products especially suitable for the feeding of animals (feed).
- Several food products may be prepared according to the invention, for example, spreads, soups, noodles, ice-cream, sauces, dressing, snacks, cereals, beverages, bread, biscuits, other bakery products, sweets, bars, chocolate, chewing gum, dairy products, dietetic products e.g. slimming products or meal replacers etc.
- The statins and soy actives are present in the food product in an amount sufficient to obtain a blood LDL-cholesterol lowering effect if the food product is used according to the common needs of the consumer.
- The skilled person will be able to adjust the percentage of statins and soy actives in the food product to get the above effect. The percentages will depend on the type of food product, since the food products are used in different serving sizes. Moreover the pattern in a food product is consumed (servings per day and distribution over days) is dependent on the food product. Data about serving sizes may be found in the list published by the United States Food and Drug Administration (FDA) titled: “Reference Amounts customarily consumed per Eating Occasion”.
- Preferably in the food products according to the invention, the amount of statin is 5-500 mg/kg and the amount of soy actives is 1 wt. or higher. More preferably the amount of soy actives is 5 wt. % or higher or 10 wt % or higher. Most preferably the amount of soy actives is 20 wt. % or higher.
- As an illustration table 2 indicates a number of products, which may be prepared according to the invention, and a typical serving size.
TABLE 2 Product Daily Serving Margarine 15 g Meat product 50 g Dressing 30 g Sweet 10 g Bar 75 g Meal replacer drink 330 ml Beverages 200 ml - Preferably the food product according to the invention comprises statin and non-glycosylated isoflavone. In soy beans and soy materials derived from soy, isoflavones are present substantially in the glycosylated form. Typically about 5 wt. % of the isoflavones is present in the non-glycosylated form. The most important glycosylated isoflavones are genistin, daidzin and glycetin. The non-glycosylated forms are respectively genistein, daidzein and glycetein. Genistein, daidzein and glycetein have been reported to have advantageous health effects, including estrogenic and antioxidant properties.
- We have found that due to the fermentation according to the invention the glycosylated isoflavones are converted into the corresponding non-glycosylated isoflavones, which are more benificial. For instance, the amount of genistein and daidzein is increased in the fermented soy compared to the non-fermented soy. Surprisingly this advantageous conversion occurs simultaneously with the production of statin.
- The invention therefore further relates to a food product wherein the amount of statin is 5-500 mg/kg, and an amount of genistein and genistin, wherein the amount of genistein is 10-99 wt. %, preferably 15-99 wt. %, more preferably 20-95 wt. %, still more preferably 20-90 wt. %, most preferably 20-80 wt. % of the sum of the amounts of genistein and genistin.
- The invention therefore further relates to a food product wherein the amount of statin is 5-500 mg/kg, and an amount of daidzein, wherein the amount of daidzein is 10-99 wt. %, preferably 15-99 wt. %, more preferably 20-95 wt. %, still more preferably 20-90 wt. %, most preferably 20-80 wt. % of the sum of the amounts of daidzein and daidzin.
- The absolute amounts of genistein and daidzein may, for each food product, be adjusted by the skilled person to a desired level. This may for instance be done by selection of the soy material to be fermented from materials having a different isoflavone content, by adjustment of the fermentation conditions, such as fermentation time, and by selecting the amount of fermented soy added to the food product. In such way the amount may be adjusted to a desired daily intake of the isoflavones, that could be for instance 50-80 mg/day for genistein. The preferred absolute level of genistein in the food products according to the invention, depends on the food type, and may be 50 mg/kg or more, more preferably 100 mg/kg or more, 200 mg/kg or more, 500 mg/kg or more and most preferably 200-5000 mg/kg. Also the absolute level of daidzein depends on the food type, and may be 50 mg/kg or more, more preferably 100 mg/kg or more, 200 mg/kg or more, 500 mg/kg or more and most preferably 200-5000 mg/kg.
- Preferably the food product according to the invention is a spread, meat product, sauce, such as soy sauce, vinegar, soup, bakery good, beverage or bar. These products are preferred because the way in which they are consumed results in a more constant intake of statins and soy actives than in other food products. More preferred food products according to the invention are a spread, cereal bar, beverage or breakfast cereal.
- The invention will now be further illustrated by the description of suitable embodiments of the more preferred food products. It belongs to the ability of the skilled person to use the teaching provided therewith to prepare other products of the invention.
- Spreads
- Typically, spreads according to the invention are oil in water or water in oil emulsions, although also spreads, which are substantially fat free, are covered. Spreads are to include margarines and liquid cooking products. The spreads may be spreadable and not pourable or may be pourable at the temperature of use e.g. 2-10° C. Fat levels may vary in a wide range e.g. full fat margarines with 60-90 wt. % of fat, medium fat margarines with 30-60 wt. % of fat, low fat products with 10-30 wt. % of fat and very low or fat free margarines with 0 to 10 wt. % of fat.
- The fat in the margarine or other spread may be any edible fat, often used are soybean oil, rapeseed oil, sunflower oil and palm oil. Fats may be used as such or in modified form e.g. hydrogenated, esterified, refined etc. Other suitable oils are well known in the art and may be selected as desired.
- The pH of a margarine or spread may advantageously be from 5.0 to 6.5, though other pH's are possible.
- Examples of spreads other than margarines are cheese spreads, sweet spreads, yoghurt spreads etc.
- Optional further ingredients of spreads may be emulsifiers, colourants, vitamins, preservatives, emulsifiers, gums, thickeners etc. The balance of the product will normally be water.
- A typical size for an average serving of margarine or other spreads is 15 grams. Preferred levels of statins in the margarine or spread are: 20-500 mg/kg statin, more preferred ranges are 50 to 250 mg/kg statin.
- Beverages
- Preferred food products according to the invention are beverages, for example tea, fruit juice, soft drinks, meal-replacers, etc. Meal replacer drinks will be described in more detail herein below. It will be apparent that similar levels and compositions apply to other beverages comprising statins and soy actives.
- A typical serving size of a beverage is taken to be 200 ml. Preferred levels of statins in a beverage are: 5-100 mg/kg, more preferably 10-80 mg/kg.
- Bars, including cereal bars
- These products often comprise a matrix of edible material wherein the statin and soy actives can be incorporated. For example the matrix may be fat based (e.g. couverture or chocolate) or may be based on bakery products (bread, dough, cookies etc). Preferably the food product is a cereal bar, in which the matrix is based on agglomerated cereal particles (rice, grain, nuts, raisins, fruit particles).
- The matrix material of a bar may be present in an amount of 60-95 wt. % of the weight of the bar, preferably 70-90 wt. % most preferred 75-85 wt %.
- Other ingredients in the cereal bar may be starch, sugar (e.g. 0-10 wt %), sirups, honey, milk solids, salt (e.g. 0-5 wt. %) calcium carbonate, vitamins, flavouring and colouring.
- The ingredients are usually mixed and cooked (e.g. by cooking-extruding) to produce the (cereal) bar.
- A typical size for a bar could be from 20 to 200 g, generally from 40 to 100 g. Preferred level in such products would be: 25 to 500 mg/kg statin. More preferred range for this level is 50 to 300 mg/kg.
- Further ingredients may be added to the product such as flavouring materials, vitamins, minerals etc.
- Preparation Of The Food Product
- According to the invention a substrate, prepared from soybeans and/or ingredients thereof is fermented with a statin producing fungus and the fermentation product is used in the preparation of a food product. These steps will be illustrated below. In this illustration the statin producing fungus is Monascus.
- Fermentation is conducted in known way. The fermentation is conducted in at least one fermentation vessel (fermenter) in which a medium comprising soybeans and/or ingredients thereof is present. The fermentation is started (inoculated) by adding a suspension of spores of the Monascus fungus (inoculum), which has been prepared by fermenting Monascus fungus on a separate medium. The fermentation may be executed batchwise or as a continuous process.
- The fermentation involves the following steps, which are executed in the given order:
- a) Preparation of the medium for the inoculum and the medium to be used in the fermenter
- b) Sterilization of the media, fermenters and ancillary equipment
- c) Production of inoculum
- d) Addition of the inoculum to the medium comprising soybeans and/or ingredients thereof, in the fermenter.
- e) Conducting the fermentation
- f) Removal of the fermentation product from the fermenter
- The fermentation product is used in the preparation of the food products according to the invention.
- Optionally, before the fermentation product is used in the preparation of the food products, the following additional process steps may be executed:
- g) Sterilization of the fermentation product
- h) Drying of the fermentation product (or sterilized fermentation product)
- i) One or more separation steps, for instance extraction, to separate statins and soy actives from Monascus biomass in the fermentation product
- The medium used in the fermenter may be solid or liquid. Advantageously the medium is solid, most preferred the medium substantially consists of crushed whole soybeans, which have been soaked with water (e.g. 30 wt % water). In case the medium is liquid, usually water is present as major constituent of the medium.
- Whole soybean are preferably used as a substrate for the fermentation. Typical composition of whole soybeans is 42% wt % protein, 20 wt % oil, 35% wt % total carbohydrates, 5 wt % ash and 5.5 wt % crude fiber (Kawamura, S., Tech. Bull. Faculty Agric., Kagawa Univ., 18, 117 (1967)).
- Instead of whole soybeans, parts or ingredients of soybean may be used in the medium for the fermenter, for instance soy protein (including textured vegetable protein), soy milk, soy-flakes etc. Care has to be taken that the medium contains compounds that can provide a carbon source and a nitrogen source for growth of the Monascus fungus.
- The Monascus fungus used according to the invention may be any Monascus fungus that produces statins. Preferably the fungus is chosen from the group of Monascus ruber Most preferred is Monascus ruber F125 M1-4.
- Strains F125 and F125 M1-4 are deposited at the Centraal Bureau voor Schimmelculturen (CBS) as no. CBS 109070 on 14.11.2000 and no. CBS 109269 on 23.01.2001.
- These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty).
- Availability of the deposited material is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.
- The medium will ordinarily be sterilized before fermentation, e.g. by heat treatment, like pasteurization.
- The medium in the fermenter may contain other substances, which may aid the fermentation, for instance sugars, amino acids and vitamins.
- The fermentation may be carried out in a manner, which can be determined by the skilled person on the basis of common general knowledge of fermentation technology. As illustration preferred embodiments are described hereunder.
- The fermentation temperature may be important. The temperature is preferably in the range of 10 to 37, ° C. more preferably 20 to 30° C. We have found that at 37° C. and higher the production of statins decreases.
- Preferably during fermentation the medium is aerated, e.g. by stirring, shaking etc. Aeration may be carried out by blowing air through the fermentation medium. Preferably the air is wholly or partly saturated with water vapour in case solid state fermentation is used. This avoids drying out of the fermentation medium.
- The relative levels of statins to soy actives will depend on the fermentation time. The fermentation time is therefore dependent on the desired amount of statins in the fermentation product. Preferred fermentation time is 1-60 days, more preferably 1-50 days, still more preferably 15-40 most preferably 20-30 days.
- Prior to addition to the food product, the fermentation product may be subjected to a separation step, to separate statins and soy actives from Monascus biomass in the fermentation product. This separation may be done with known separation techniques, e.g. filtration or centrifugation.
- The fermentation product may also be extracted and extract may be used in the preparation of the food product. Preferred extraction agents are food-grade extraction agents. More preferred extraction agent is ethanol. Most preferred extraction agent is vegetable oil, e.g. soybean oil or sunflower oil.
- The extraction may be done on the fermentation product. Alternatively the Monascus biomass may be separated from the fermentation product prior to extraction, e.g. by filtration. The Monascus biomass may be separately extracted and the resulting extract can also be used in the preparation of the food product.
- Extracts may be used as such in the preparation of food products. Preferably extraction solvent may be removed from the extracts, e.g. by evaporation of the extraction solvent.
- Advantageously edible oil may be used as extractant, the edible oil is preferably vegetable oil, such as for instance soy bean oil or sunflower oil. When the fermentation product is extracted with vegetable oil, it was found that the statin is effectively extracted and an oil phase containing substantially all statin is obtained. The resulting extract is very suitable to be used directly as a food ingredient.
- Most advantageously the extractant, e.g. vegetable oil is added to the fermentation medium during fermentation. We have found that in the presence of an extractant, the production of statins during fermentation is considerably increased. It is possible to increase the amount of statin produced by at least a factor 10, more preferably at least a factor 40, compared to fermentation without extractant, by the addition of vegetable oil during the fermentation. Preferably the extractant should not interfere with the fermentation, especially it should not be poisonous for the statins producing fungus. The amount of oil is preferably at least 5 wt. % oil (w/w on substrate), more preferably more than 10 wt. %, most preferably at least 20 wt. %, being present in the substrate during fermentation. Preferably the oil is edible oil, more preferably vegetable edible oil, such as for instance sunflower oil or soybean oil. Though animal and vegetable fat may be used these are less preferred for hearth health reasons.
- The fermentation product (including extracts etc.) may directly be added to food product ingredients in the process of preparation of the food products according to the invention. It can be added to the other ingredients of the food product composition, or it may be added to part of the ingredients, before other ingredients are added. If more than one phase is present in the food product the fermentation product may be present in one or more of these phases. Preferably the fermentation product will substantially be present in an oil phase, if such oil phase is present.
- A. Preparation of Monascus strain F125 M1-4
- Monascus ruber strain F125 was cultivated in malt water liquid medium at 30° C. for 4 days. Of this culture, 1 ml was used as an inoculum for a Hybond-N filter (Amersham, UK) placed on a YE plate (4% glucose, 0.3% KH2PO4, 1.0% yeast extract (Difco), 1.5% agar). After 3 days incubation at 30° C., the spores were harvested by washing the filters with 10 ml physiological saline containing 0.1% Tween 80. The spores were filtered 4 times through Mira cloth filters to obtain a hyphae free spore suspension. This suspension was used for subsequent mutagenesis.
- The spores were diluted to a concentration of 108 spore/ml then exposed to UV light at an intensity of 100 joules/m2. The mutagenised spores were plated on Potato Dextrose Agar (Oxoid) and incubated for 3 weeks. One of the resulting colonies, which had a lighter colour than the others was selected and is herein defined as Monascus strain F125 M1-4.
- B. Preparation of Monascus spores
- Monascus f125M1-4 spores were prepared by harvesting Monascus mycelium from a PDA (potato dextrose agar) (oxoid) slope by washing with 5 ml physiological saline and incubating the mycelium in 150 ml malt water (oxoid) for 4 days at 30° C. The spores were harvested by filtration through a Mira cloth filter.
- C. Fermentation
- C.1. Preparation Of An Inoculum
- A shake flask containing soybeans is inoculated with filamentous spores suspended in a physiological water solution containing 0.1 wt % Tween 80 (polyoxyethylene sorbitan fatty acid ester, available from ICI Specialty Chemicals™). This shake flask is incubated to let the mould grow. This resulted in a Monascus spore suspension, which was adjusted by dilution to a concentration of 1*106 spores/ml.
- C.2. Preparation Of Fermentation Medium
- 1 kg of soybeans is soaked in tap water (50° C.) for 30 minutes. After soaking the beans are rinsed with cold tap water. Subsequently 50 g batches of the soaked beans (97% soybean) were brought in to 300 ml Erlenmeyer flasks.
- C.3. Fermentation
- The shake flasks were each inoculated with 1 ml of the prepared Monascus spore suspension and incubated for 30 days at 30° C. A sample from the shake flask was taken every week to monitor the statin production.
- After fermentation, about 600 g soybeans remained.
- D. Statin analysis of fermentation product
- The fermentation product samples are extracted in a 50 ml tube (Falcon) by adding 6 ml of a mixture of acetonitril, water and phosphoric acid (1:1:0.05, v/v/v). The mixture is blended with an Ultraturrax for 1 min. The mixture was then incubated at room temperature on a rollerbank for over 24 hours. Hereafter the samples were centrifuged and the supernatant liquid used for HPLC analysis. Samples were separated using HPLC analysis on a Shimadzu apparatus according to the method of Morovjan et al., J. chromatogr. A 763 (1997) 165-172. The system consists of the Shimadzu SCL-10A system controller, CTO-10AS column oven, LC-10AT vp pump system, RID-10A refraction index detector, SPD-M10A diode array detector and SIL-10AD autoinjector. For the chromatographic determination of statins a Waters NovaPak C18 (150×3.9 mm I.D., 4 μm) column was used operating at 25° C. The eluent was acetonitril-0.1% phosphoric acid (50:50,v/v) solution flowing at 1.5 ml/min. Runs were performed for 15 min. The detection was performed using a diode array detector from 190 nm up to 800 nm. The sum of the area of all peaks in the spectrum belonging to statins is measured. Comparison to a standard (Mevinolin, Sigma) allows the calculation of a statin content (expressed in mg/kg analysed product).
- The analysis results in a statin content of 1200 mg/kg product.
- E. Extraction of the fermentation product
- The fermentation product was extracted with ethanol and acetonitril. The soybean extracts contained 0.0545 g statin/kg (ethanol extract) or 0.0978 g statin/kg (acetonitril extract) as determined by HPLC, as described under D.
- F. Colour analysis of extract
- When colours are classified, they can be broken down into the three primary elements. One is the Hue (colour) the other is Value (brightness) and the third is Chroma (Saturation like vivid colours or dull colours).
- To enable anyone to tell anyone else exactly what colour they are talking about a common numerical code is used. This numerical code used is L*a*b*. When a colour is expressed in this system, Value becomes L*, while Hue and Chroma are expressed as a* and b* respectively. The L*a*b* was measured of different time samples during fermentation. The supernatant of the samples was filtered sterilized with a milipore 0.22 μm filter. Of the clear liquid L*a*b* was measured with a UV 1601 spectofotometer of Shimatzu.
- L*a*b* values of the soy extracts
- Soy fermented with M. ruber M1-4
- L*=90.2 ; a*=−4.8 ; b*=33.8
- G. Preparation of a pourable margarine
- An ethanol extract of the fermentation product was used for further processing. Ethanol was removed by means of rotary evaporator. The residue was used in a pourable margarine composition. A pourable margarine composition without fermentation product residue was used for comparison with respect to colour.
- The composition of the pourable margarine is given in table 3.
TABLE 3 Composition of the pourable margarine of example 1. Amount Ingredient (wt. % on total) Sunflower oil 79.6 Rapeseed oil 1.95 hardened to a melting temperature of 70° C. Lecithin (BOLEC MT) 0.18 Lecithin (Cetinol) 0.2 Potassium sorbate 0.0125 Water 18.0 Statins 0.00011 - The colour of the pourable margarine was not different from a control with no statins extract, but 20 wt. % water.
- Example 1, steps B to G were repeated, but instead of Monascus strain F125 M1-4, a Monascus strain isolated from red rice (commercial product from China) was used.
- The L*a*b* values of the extracts were determined according to example 1, step F. These values were:
- L*=90.2 ; a*=56.1; b*=63.9
- The procedure of example 1, steps B to G. was repeated, however in step C.2., instead of 1 kg of soybeans, 1 kg of rice (Parboiled rice, Oryza) was used. After fermentation about 500 g rice remained.
- The L*a*b* values of the extracts were determined according to example 1, step F. These values were
- L*=80 a*=54; b*=49
- A spread having the composition as in table 4 was prepared.
TABLE 4 Composition of spread of example 2 Ingredient Amount (wt % on total) Sunflower oil 69.295 Fat blend 10.5 Beta carotene 0.125 Monoglygceride (Hymono 0.08 8903) Water 13.33 Ethanol extract of 6.67 example 1C Total 100 - The fat blend was a mixture of 65 wt. % mid fraction of palm oil stearin and 35 wt % palm kernel oil.
- The spread was prepared by premixing the ingredients in a premix tank at 55° C. in a premix tank and feeding the premix to a Votator with two scraped surface heat exchangers (A-units) operated at 800 rotations per minute (rpm) and one crystallizer (C-unit) operated at 200 rpm. The configuration was A-A-C.
- The amount of statin in the spread was 74 mg/kg. The colour of the spread was not different from a control with no statins extract, but 20 wt. % water.
- Fermentation with oil addition
- 10 litre reactors were filled with 8 litres substrate (Glucose 20 9/1, glycerol 100 g/l, starch 20 g/l, NaNO3 2 g/l MgSO4 5 g/l) and set to an airflow of 6 volume change per minute (vvm). A pre-culture was prepared in YPD at 30° C. for two days and used to inoculate the fermentor with a concentration of 1×10 7 spores/l Monascus ruber F125M1-4. The cultures were incubated at 25° C. and 200 rpm for 3 weeks. After 22 days, 400 ml soybean oil was added to the 10 litre reactor.
- After 49 days the fermentation was stopped and the amount of statins in the water and the oil phase were measured. The results are shown in Table 5.
TABLE 5 Amount of statin (mg/l) in the different phases after 49 day of fermentation. Water phase Oil phase Total Volume of the phase 6.6 0.4 7 Statin (mg/l) 2.37 1420 83.4 - At the end of the fermentation 97 wt % of the statins were found in the oil phase. A big difference is seen between the statin levels in the oil and the water phase. The supplementation of oil increases the total amount of statin in the reactor. A control reactor without oil supplementation contained 1.8 mg/l statins, while the reactor with oil supplementation shows a total amount of 83.4 mg/l statins. The reactor with oil supplementation shows a 45 times higher statin content compared with the amount of statins in the fermentation without oil.
- Addition of soybean oil to solid state fermentations also stimulated the production of statin.
- Steps A, B and D. were done according to example 1.
- C. Fermentation
- C.1. Preparation of an Inoculum
- A shake flask containing dehulled soybeans is inoculated with filamentous spores suspended in a physiological water solution containing 0.1 wt % Tween 80 (polyoxyethylene sorbitan fatty acid ester, available from ICI Specialty Chemicals™). This shake flask is incubated to let the mould grow. This results in a Monascus spore suspension, which was adjusted by dilution to a concentration of 1*106 spores/ml.
- C.2. Preparation of Fermentation Medium
- 1 kg of dehulled soybeans were soaked in tap water (50° C.) for 30 minutes and subsequently air dried for two hours. Subsequently 50 g batches of the dried dehulled beans were brought in to 300 ml Erlenmeyer flasks.
- C.3. Fermentation
- The shake flasks were each inoculated with 1 ml of the prepared Monascus spore suspension and incubated for 30 days at 30° C. A sample from the shake flask was taken every week to monitor the statin production.
- After fermentation, about 600 g soybeans remained. The analysis according to step D results in a statin content of 2800 mg/kg product.
- E. Isoflavone analysis of fermentation product
- The isoflavone concentration was measured according to the HPLC method described in Franke A.A., et al. (1998): HPLC analysis of isoflavonoids and other phenolic agents from foods and human fluids;Proceed. Soc. Exp. Biol. Med; 217 (3), 274-280.
- Two samples were tested. The first (comparative) sample was taken from non-fermented fermentation medium, as prepared in step C2 above. The second sample was of equal (solid) weight, but taken from the fermentation product. The results of the isoflavone measurement of these samples are given in table 3.
TABLE 3 Isoflavone concentration in fermented and non- fermented soy Isoflavone concentration (g/kg) Fermentation medium Fermentation Isoflavone (unfermented) product Daidzin 1.107 0.304 Genistin 1.608 0.476 Daidzein 0.057 0.9 Genistein 0.085 0.494 Total 2.9 2.2 - Table 3 shows that the amount of isoflavones in total in the fermentation product is slightly decreased compared to the non-fermented material, but surprisingly the amounts of genistein and daidzein are increased. The fermentation product contains substantial amounts of isoflavones in addition to the statin.
Claims (18)
1. Process for the preparation of one or more statins by fermentation, wherein a substrate is fermented with statins producing fungus, characterized in that substrate comprises more than 20% by weight of soy ingredients.
2. Process according to claim 1 , wherein the substrate comprises more than 50% by weight of soy ingredients.
3. Process according to claim 1 , wherein the substrate comprises more than 80% by weight of soy ingredients.
4. Process according to any one of claims 1, wherein the statins producing fungus is a Monascus fungus.
5. Process according to any one of claims 1, wherein an amount of oil being at least 5 wt. % oil is present in the substrate during fermentation.
6. Process according to claim 5 , wherein the oil is edible oil.
7. Process according to claim 5 , wherein the oil is vegetable edible oil.
8. Process according to any of claims 5, wherein the amount of oil is at least 10 wt. %.
9. The Monascus strain F125 M1-4 deposited at the Centraal Bureau voor Schimmelculturen on 14.11.2000 having number CBS 109070.
10. Food product comprising:
a) an amount of one or more statins,
b) an amount of one or more compounds chosen from the group: polyunsaturated fatty acids, phytosterols, proteins, peptides, dietary fibers, polyphenols and saponins, wherein the food product has a Hue a* value less than 20.
11. Food product according to claim 10 , wherein the amount of one or more statins is 5-500 mg/kg, comprising an amount of genistein and genistin, wherein the amount of genistein is 10-99 wt. % of the sum of the amounts of genistein and genistin.
12. Food product according to claim 11 , wherein the amount of genistein is 20-95 wt. % of the sum of the amounts of genistein and genistin.
1. Food product according to claim 11 , wherein the amount of genistein is 20-80 wt. % of the sum of the amounts of genistein and genistin.
13. Food product according to claim 10 , wherein the amount of
a) is 5-500 mg/kg and the amount of b) 1 wt. or higher.
14. Food product according to claim 14 , wherein the amount of
b) is 5 wt. % or higher.
15. Food product according any one of claims 10, wherein the food product has a Hue a* value less than 10.
16. Food product according to claim 10 , wherein the one or more compounds chosen from the group: polyunsaturated fatty acids, phytosterols, proteins, peptides, dietary fibers, polyphenols and saponins are substantially derived from soybeans.
17. Food product according to claim 10 , wherein the food product is a margarine, dressing, sweet, bar meal replacer, breakfast cereal or beverage.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01200489.1 | 2001-02-09 | ||
EP01200493 | 2001-02-09 | ||
EP01200489 | 2001-02-09 | ||
EP01200493.3 | 2001-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030108657A1 true US20030108657A1 (en) | 2003-06-12 |
Family
ID=26076831
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/072,570 Abandoned US20030108657A1 (en) | 2001-02-09 | 2002-02-08 | Process for the preparation of one or more statins by frementation |
US10/072,580 Expired - Fee Related US6849281B2 (en) | 2001-02-09 | 2002-02-08 | Food product suitable for reducing low density lipoprotein cholesterol levels |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/072,580 Expired - Fee Related US6849281B2 (en) | 2001-02-09 | 2002-02-08 | Food product suitable for reducing low density lipoprotein cholesterol levels |
Country Status (7)
Country | Link |
---|---|
US (2) | US20030108657A1 (en) |
EP (2) | EP1357807B1 (en) |
CN (2) | CN1273608C (en) |
AT (1) | ATE356554T1 (en) |
AU (1) | AU2002235885A1 (en) |
DE (1) | DE60218822T2 (en) |
WO (2) | WO2002063976A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050175751A1 (en) * | 2004-02-09 | 2005-08-11 | Cheng-Jen Lin | Method of extracting isoflavon from soybeans |
US20070218185A1 (en) * | 2004-04-28 | 2007-09-20 | Beindorff Christiaan M | Edible Oil Containing Statins |
WO2010022073A1 (en) * | 2008-08-19 | 2010-02-25 | Dbc, Llc | Compositions and methods for utilizing the same |
EP2243383A3 (en) * | 2005-04-06 | 2011-02-16 | Nestec S.A. | A method and composition for nutritionally improving glucose control and insulin action |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050025812A1 (en) * | 2003-07-10 | 2005-02-03 | Forest Carl A. | Salad dressing with weight loss supplement |
US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
KR100379075B1 (en) * | 2002-03-07 | 2003-04-08 | Jinis Biopharmaceuticals Co | Method for producing low cholesterol animal food product and food product therefrom |
DE602004023536D1 (en) * | 2003-12-18 | 2009-11-19 | Unilever Nv | Süssware |
AU2005237214B2 (en) * | 2004-04-28 | 2008-05-22 | Unilever Plc | Composition comprising statins |
US20050281932A1 (en) * | 2004-06-18 | 2005-12-22 | Good Humor - Breyers Ice Cream | Frozen confection |
JP2008506773A (en) * | 2004-07-19 | 2008-03-06 | ティア メディカ アクスイェ セルスカプ | Composition comprising protein material and non-oxidizing fatty acid body |
CN101014254A (en) * | 2004-08-23 | 2007-08-08 | 荷兰联合利华有限公司 | Composition comprising statin |
US8486469B2 (en) * | 2005-10-17 | 2013-07-16 | Intercontinental Great Brands Llc | Low-calorie food bar |
EP2036444A1 (en) * | 2007-09-05 | 2009-03-18 | Dietetics Pharma S.r.l. | Liquid nutraceutic preparation containing free plant sterols |
MY160246A (en) * | 2009-04-08 | 2017-02-28 | Nanyang Polytechnic | A plant extract comprising statins and preparation techniques and uses thereof |
CN102803501B (en) * | 2010-01-29 | 2014-07-30 | 株式会社爱茉莉太平洋 | Method for preparing coumestrol and coumestrol prepared by same |
WO2012063985A2 (en) * | 2010-11-12 | 2012-05-18 | 김용문 | Hamburger for cholesterol reduction and manufacturing method therefor |
GB201115417D0 (en) | 2011-09-06 | 2011-10-19 | Ip Science Ltd | Products and methods |
CN105124424A (en) * | 2015-07-27 | 2015-12-09 | 黄琪淋 | Instant bamboo-tube-cooked red rice capable of lowering lipid and reducing blood pressure and making method thereof |
ITUA20162441A1 (en) * | 2016-04-08 | 2017-10-08 | Massimo Farinon | FOOD PASTA |
CN108925833A (en) * | 2018-07-24 | 2018-12-04 | 黄山大地绿宁生物科技有限公司 | A kind of fermentation freeze-drying rice is dilute and its production method |
CN112335836A (en) * | 2020-10-23 | 2021-02-09 | 湖南侗都米业股份有限公司 | Preparation method of red rice glutinous rice cake |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4218489A (en) * | 1977-06-08 | 1980-08-19 | Z-L Limited Partnership | Antioxidants, antioxidant compositions and methods of preparing and using same |
US5670632A (en) * | 1996-01-18 | 1997-09-23 | Acds Technologies, Ltd. | Process for obtaining an isoflavone concentrate from a soybean extract |
US5674892A (en) * | 1994-10-28 | 1997-10-07 | Cor Therapeutics, Inc. | Method and compositions for inhibiting protein kinases |
US5830887A (en) * | 1992-05-19 | 1998-11-03 | Novogen Research Pty. Ltd. | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
US6046022A (en) * | 1996-09-30 | 2000-04-04 | Peking University | Methods and compositions employing red rice fermentation products |
US6165512A (en) * | 1998-10-30 | 2000-12-26 | Fuisz Technologies Ltd. | Dosage forms containing taste masked active agents |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5925599B2 (en) * | 1979-02-20 | 1984-06-19 | 三共株式会社 | New physiologically active substance monacolin K and its production method |
US5250435A (en) * | 1991-06-04 | 1993-10-05 | Merck & Co., Inc. | Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I) |
NZ245713A (en) * | 1992-02-10 | 1994-12-22 | Novopharm Ltd | Production of the antibiotic lovastatin from genetically engineered aspergillus strains |
AU715424B2 (en) * | 1996-02-29 | 2000-02-03 | Nutri Pharma Asa | Composition and its use as a food supplement or for lowering lipids in serum |
MY116591A (en) * | 1996-04-26 | 2004-02-28 | Hoffmann La Roche | Process for the production of lipstatin and tetrahydrolipstatin |
CZ326896A3 (en) * | 1996-11-07 | 1998-05-13 | Milo Olomouc, A. S. | Fat with specific antisclerotic activity |
ATE253925T1 (en) * | 1998-11-25 | 2003-11-15 | Nutri Pharma As | COMPOSITION CONTAINING SOY PROTEIN, DIETARY FIBERS AND PHYTOESTROGEN AND THEIR USE FOR PREVENTING AND/OR TREATING CARDIOVASCULAR DISEASES |
US20020160060A1 (en) | 1999-04-26 | 2002-10-31 | Mandy Kim Chen | Enriched spreads |
HUP9902352A1 (en) * | 1999-07-12 | 2000-09-28 | Gyógyszerkutató Intézet Kft. | Process for producing pravastatin by microbiological way |
CN1272368A (en) * | 2000-04-28 | 2000-11-08 | 谢申猛 | Selenium-enriched anka for reducing blood-fat and blood sugar |
EP1176208A1 (en) * | 2000-07-28 | 2002-01-30 | Société des Produits Nestlé S.A. | Koji molds and use thereof for preparing cholesterol-lowering products |
-
2002
- 2002-01-30 WO PCT/EP2002/000998 patent/WO2002063976A1/en active IP Right Grant
- 2002-01-30 EP EP02719746A patent/EP1357807B1/en not_active Expired - Lifetime
- 2002-01-30 CN CNB02804794XA patent/CN1273608C/en not_active Expired - Fee Related
- 2002-01-30 DE DE60218822T patent/DE60218822T2/en not_active Expired - Fee Related
- 2002-01-30 CN CNB028048083A patent/CN100456962C/en not_active Expired - Fee Related
- 2002-01-30 EP EP02702333A patent/EP1358343A2/en not_active Withdrawn
- 2002-01-30 AT AT02719746T patent/ATE356554T1/en not_active IP Right Cessation
- 2002-01-30 WO PCT/EP2002/000999 patent/WO2002064809A2/en not_active Application Discontinuation
- 2002-01-30 AU AU2002235885A patent/AU2002235885A1/en not_active Abandoned
- 2002-02-08 US US10/072,570 patent/US20030108657A1/en not_active Abandoned
- 2002-02-08 US US10/072,580 patent/US6849281B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4218489A (en) * | 1977-06-08 | 1980-08-19 | Z-L Limited Partnership | Antioxidants, antioxidant compositions and methods of preparing and using same |
US5830887A (en) * | 1992-05-19 | 1998-11-03 | Novogen Research Pty. Ltd. | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
US5674892A (en) * | 1994-10-28 | 1997-10-07 | Cor Therapeutics, Inc. | Method and compositions for inhibiting protein kinases |
US5670632A (en) * | 1996-01-18 | 1997-09-23 | Acds Technologies, Ltd. | Process for obtaining an isoflavone concentrate from a soybean extract |
US6046022A (en) * | 1996-09-30 | 2000-04-04 | Peking University | Methods and compositions employing red rice fermentation products |
US6165512A (en) * | 1998-10-30 | 2000-12-26 | Fuisz Technologies Ltd. | Dosage forms containing taste masked active agents |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050175751A1 (en) * | 2004-02-09 | 2005-08-11 | Cheng-Jen Lin | Method of extracting isoflavon from soybeans |
US20070218185A1 (en) * | 2004-04-28 | 2007-09-20 | Beindorff Christiaan M | Edible Oil Containing Statins |
EP2243383A3 (en) * | 2005-04-06 | 2011-02-16 | Nestec S.A. | A method and composition for nutritionally improving glucose control and insulin action |
US8697630B2 (en) | 2005-04-06 | 2014-04-15 | Nestec S.A. | Method for lowering insulin resistance |
WO2010022073A1 (en) * | 2008-08-19 | 2010-02-25 | Dbc, Llc | Compositions and methods for utilizing the same |
US20110151031A1 (en) * | 2008-08-19 | 2011-06-23 | Dbc, Llc | Compositions and methods for utilizing the same |
Also Published As
Publication number | Publication date |
---|---|
CN1491284A (en) | 2004-04-21 |
DE60218822T2 (en) | 2007-07-12 |
US6849281B2 (en) | 2005-02-01 |
CN1273608C (en) | 2006-09-06 |
DE60218822D1 (en) | 2007-04-26 |
WO2002064809A3 (en) | 2003-04-24 |
EP1357807A1 (en) | 2003-11-05 |
AU2002235885A1 (en) | 2002-08-28 |
EP1358343A2 (en) | 2003-11-05 |
ATE356554T1 (en) | 2007-04-15 |
WO2002064809A2 (en) | 2002-08-22 |
US20030104004A1 (en) | 2003-06-05 |
EP1357807B1 (en) | 2007-03-14 |
CN100456962C (en) | 2009-02-04 |
WO2002063976A1 (en) | 2002-08-22 |
CN1491085A (en) | 2004-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030108657A1 (en) | Process for the preparation of one or more statins by frementation | |
EP0956774B1 (en) | Edible fats containing arachidonic acid and foods containing the same | |
EP1709969A1 (en) | Health promoting dairy and food products containing mushroom glucan produced through fermentation of Grifola frondosa | |
AU2005237213B2 (en) | Edible oil containing statins | |
JP2022531891A (en) | Method for producing hyphalized weight-increasing composition | |
AU2005237214B2 (en) | Composition comprising statins | |
KR20170055356A (en) | soybean meat containing large quantity of conjugated linoleic acid and isoflavone and manufacturing method thereof | |
JP2002142789A (en) | Method for obtaining sod-like active fraction and antioxidative active fraction by fermenting defatted sesame, and sod-like active fraction and antioxidative active fraction obtained from the same | |
Baldwin | Application for Approval of DHA-rich Oil | |
CN1943409A (en) | Process for the preparation of one or more statins by fermentation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNILEVER BESTFOODS, NORTH AMERICA, DIVISION OF CON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VAN OORSCHOT, GIJSBERTUS JOHANNES;TER SCHURE, EELKO;TRAUTWEIN, ELKE;REEL/FRAME:012984/0153 Effective date: 20020314 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |